Update on systemic therapies for atopic dermatitis

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 4, 2012, Pages 421-426

  Denby, Kristopher S ^a   Beck, Lisa A ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

atopic dermatitis; immunomodulation; phototherapy; systemic therapies

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AZATHIOPRINE; CYCLOSPORIN A; GAMMA INTERFERON; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TOCILIZUMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ATOPIC DERMATITIS; BACTERIAL INFECTION; BURSITIS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; CONJUNCTIVITIS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; ENTERITIS; FOLLOW UP; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; LARGE VESSEL VASCULITIS; LONG TERM CARE; LYMPHOCYTOPENIA; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; PEMPHIGUS VULGARIS; PHOTOTHERAPY; POLYMYOSITIS; PRIORITY JOURNAL; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; SARCOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTEMIC THERAPY; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VASCULITIS;

AZATHIOPRINE; CYCLOSPORINE; DERMATITIS, ATOPIC; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPOSI VARICELLIFORM ERUPTION; MALE; METHOTREXATE; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84864279964     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3283551da5     Document Type: Review

References (39)

1. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2:1323-1327. (Pubitemid 9078430)
2. Remuzzi G, Lesti M, Gotti E, et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomized trial. Lancet 2004; 364:503-512. (Pubitemid 39070410)
3. Haeck IM, Knol MJ, Ten Berge O, et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011; 64:1074-1084.
4. Ogata A, Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol 2012; 2012:946048.
5. Navarini AA, French LE, Hofbauer GF. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 2011; 128:1128-1130.
6. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371:987-997. (Pubitemid 351392039)
7. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57:622-628. (Pubitemid 47384928)
8. Hansen TM, Kryger P, Elling H, et al. Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis. BMJ 1990; 301:268-270. (Pubitemid 20241227)
9. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000; 19:14-16. (Pubitemid 30048938)
10. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002; 147:324-330.
11. Lipsmeyer EA. Development of malignant cerebral lymphoma in a patient with systemic lupus erythematosus treated with immunosuppression. Arthritis Rheum 1972; 15:183-186.
12. Doak PB, Montgomerie JZ, North JD, Smith F. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br Med J 1968; 4:746-748.
13. Siegel JH, Janis R, Alper JC, et al. Disseminated visceral Kaposis sarcoma: appearance after human renal homograft operation. JAMA 1969; 207:1493-1496.
14. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121-1125. (Pubitemid 41025906)
15. Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258794.htm. [Accessed 6 January 2012]
16. Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED. Hepatosplenic T-cell lymphoma in patients receiving TNF-alpha inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol 2011; 23:1150-1156.
17. Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114:154-163. (Pubitemid 40082381)
18. Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011; 128:353-359.
19. Todd PA, Goa KL. Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease. Drugs 1992; 43:111-122.
20. Key LL Jr, Ries WL, Rodriguiz RM, Hatcher HC. Recombinant human interferon gamma therapy for osteopetrosis. J Pediatr 1992; 121:119-124.
21. Frisch S, Siegfried EC. The clinical spectrum and therapeutic challenge of eczema herpeticum. Pediatr Dermatol 2011; 28:46-52.
22. Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol 2002; 27:3-7. (Pubitemid 34309928)
23. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91:602-607. [see comment]. (Pubitemid 23064146)
24. Ozen A, Baris S, Karakoc Aydiner E, et al. Experience with intravenous immunoglobulin in severe childhood atopic dermatitis. Allergol Immunopathol (Madr) 2012; 40:131-133.
25. Jee SJ, Kim JH, Baek HS, et al. Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis. Allergy Asthma Immunol Res 2011; 3:89-95.
26. Fidan E, Onder Ersoz H, Yilmaz M, et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol 2011; 48:297-302.
27. Behshad R, Cooper KD, Korman NJ. A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch Dermatol 2008; 144:84-88. (Pubitemid 351159393)
28. Jung K, Tanaka A, Fujita H, et al. Peroxisome proliferator-activated receptor gamma-mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC/Tnd mice. J Allergy Clin Immunol 2011; 127:420-429; e421-e426.
29. Schmuth M, Jiang YJ, Dubrac S, et al. Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 2008; 49:499-509.
30. Hatano Y, Elias PM, Crumrine D, et al. Efficacy of combined peroxisome proliferator-activated receptor-alpha ligand and glucocorticoid therapy in a murine model of atopic dermatitis. J Invest Dermatol 2011; 131:1845-1852.
31. Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broadband ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357:2012-2016. (Pubitemid 32592389)
32. Krutmann J, Czech W, Diepgen T, et al. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992; 26 (2 Pt 1):225-230.
33. Krutmann J, Diepgen TL, Luger TA, et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998; 38:589-593. (Pubitemid 28182930)
34. Pavlovsky M, Baum S, Shpiro D, et al. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? J Eur Acad Dermatol Venereol 2011; 25:727-729.
35. Heinlin J, Schiffner-Rohe J, Schiffner R, et al. A first prospective randomized controlled trial on the efficacy and safety of synchronous balneophototherapy vs. narrow-band UVB monotherapy for atopic dermatitis. J Eur Acad Dermatol Venereol 2011; 25:765-773.
36. Tintle S, Shemer A, Suarez-Farinas M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011; 128:583-593; e581-e584.
37. Autio P, Komulainen P, Larni HM. Heliotherapy in atopic dermatitis: a prospective study on climatotherapy using the SCORAD index. Acta Derm Venereol 2002; 82:436-440. (Pubitemid 36140245)
38. Vahavihu K, Ylianttila L, Salmelin R, et al. Heliotherapy improves vitamin D balance and atopic dermatitis. Br J Dermatol 2008; 158:1323-1328. (Pubitemid 351692863)
39. Byun HJ, Lee HI, Kim B, et al. Full-spectrum light phototherapy for atopic dermatitis. Int J Dermatol 2011; 50:94-101.